We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MITO
151
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$350K 0.05%
501,836
+23,275
+5% +$15.7K
CDAK
152
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$328K 0.04%
52,177
+2,497
+5% +$15.7K
BGMS
153
Bio Green Med Solution Inc
BGMS
$4.91M
$319K 0.04%
29
+1
+4% +$12.1K
MREO
154
Mereo BioPharma
MREO
$54.7M
$318K 0.04%
915,856
+62,176
+7% +$80.4K
GYRE icon
155
Gyre Therapeutics
GYRE
$641M
$314K 0.04%
63,550
+2,971
+5% +$14.7K
ONCT
156
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$292K 0.04%
10,509
+550
+6% +$20K
EYPT icon
157
EyePoint Inc
EYPT
$1.03B
$274K 0.04%
22,552
+1,125
+5% +$12.3K
AGEN
158
Agenus
AGEN
$312M
$267K 0.04%
5,550
+292
+6% +$15.8K
GNCA
159
DELISTED
Genocea Biosciences, Inc.
GNCA
$259K 0.03%
206,336
+9,515
+5% +$10.4K
BIIB icon
160
Biogen
BIIB
$30B
$237K 0.03%
1,122
-28,411
-96% -$6.18M
PASG icon
161
Passage Bio
PASG
$14.4M
$223K 0.03%
3,593
+201
+6% +$16.6K
SEEL
162
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$215K 0.03%
67
+3
+5% +$12.9K
TPST icon
163
Tempest Therapeutics
TPST
$13.7M
$210K 0.03%
4,756
+233
+5% +$10.6K
LRMR icon
164
Larimar Therapeutics
LRMR
$397M
$209K 0.03%
51,606
+4,413
+9% +$28.9K
ACRS icon
165
Aclaris Therapeutics
ACRS
$726M
$208K 0.03%
12,124
+1,339
+12% +$18.3K
ALNY icon
166
Alnylam Pharmaceuticals
ALNY
$27.5B
$201K 0.03%
1,237
+42
+4% +$6.4K
KOD icon
167
CALL
Kodiak Sciences
KOD
$2.6B
$199K 0.03%
25,700
-142,200
-85% -$5.55M
ATYR
168
aTyr Pharma
ATYR
$47.6M
$197K 0.03%
37,017
+1,969
+6% +$11.2K
ASLN
169
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$192K 0.03%
24,269
+1,335
+6% +$49.6K
IVA
170
Inventiva
IVA
$1.06B
$178K 0.02%
15,579
+831
+6% +$10.1K
DRUG
171
Bright Minds Biosciences
DRUG
$719M
$161K 0.02%
21,192
+1,192
+6% +$13.4K
OCUL icon
172
Ocular Therapeutix
OCUL
$1.79B
$147K 0.02%
29,644
+2,093
+8% +$11.6K
APTO
173
DELISTED
Aptose Biosciences, Inc.
APTO
$147K 0.02%
238
+11
+5% +$6.08K
PBYI icon
174
Puma Biotechnology
PBYI
$404M
$144K 0.02%
49,843
– –
ENVB icon
175
Enveric Biosciences
ENVB
$6.32M
$141K 0.02%
47
+3
+7% +$13.3K
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.